Henriksen et al. investigated the clinical utility of UGT1A1 genotyping to guide dose adjustments for metastatic renal cell carcinoma patients treated with pazopanib who developed liver toxicity [20]. The gene discussed is UGT1A1; the disease is hepatotoxicity.